Drug middlemen have slim profit margins — Just ask them

  NEW YORK - Companies of all kinds try to present their financial results in the best light possible to attract investors. One segment of the drug industry is bucking that trend, using an accounting method that narrows its profit margins. The three big middlemen for prescription drugs, known as pharmacy benefit managers, or PBMs, had operating-profit margins…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.